Navigation Links
KV Pharmaceutical's Launch of Gestiva(TM) Delayed
Date:1/26/2009

ST. LOUIS, Jan. 26 /PRNewswire-FirstCall/ -- KV Pharmaceutical (NYSE: KVa/KVb) has been notified that the pending New Drug Application (NDA) for Gestiva(TM) (alpha hydroxyprogesterone caproate) will not be approved by the U.S. Food and Drug Administration (FDA) until further conditions are met.

As previously disclosed, KV Pharmaceutical entered into a purchase agreement to acquire the U.S. and worldwide rights to Gestiva upon approval of the pending NDA, which was under review by the FDA. The Company previously announced that the date on which the FDA was expected to issue a decision was January 25, 2009.

The Company has been informed by the current NDA applicant that the FDA will not approve Gestiva until additional data and information is submitted and accepted. The NDA applicant and the Company have agreed to certain FDA- suggested revisions to the protocol for a post-approval clinical trial that the parties had previously agreed to conduct. However, the agency has now concluded that an additional condition for approval, among others, will be that a portion of the study subjects must be enrolled in the study prior to final approval. As a result, the Company does not anticipate that it will generate revenues from sales of Gestiva during this fiscal year, which ends on March 31, 2009.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology- distinguished branded and generic/non-branded prescription pharmaceutical products. The company markets its technology distinguished products through ETHEX Corporation, a national leader in generic pharmaceuticals and Ther-Rx Corporation, its branded drug subsidiary.


'/>"/>
SOURCE KV Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
2. University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing
3. Amylin Pharmaceuticals to Webcast Year-End Results
4. Renhuang Pharmaceuticals, Inc. Engages New Independent Auditor
5. NUCRYST Pharmaceuticals appoints a new director
6. Access Pharmaceuticals Provides an Update on Advances In Its Cobalamin(TM) Oral Drug Delivery Product Development
7. S&R Communications Group Partners With Ovation Pharmaceuticals to Launch Xenazine* (tetrabenazine)
8. Dana-Farber Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
9. Alexion Pharmaceuticals To Report Fourth Quarter and Full Year 2008 Results on February 12, 2009
10. Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements
11. Medimetriks Pharmaceuticals Launches Companys First Prescription Brands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 27, 2017 , ... The Case Management Society of America (CMSA) will install ... CMSA’s membership has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to ... new VA Advisory position has also been added to the BOD, per an appointment ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... today announced the launch of a new research study, The Business Readiness Report. ... to execute that strategy, and the actual success of achieving individual and company ...
(Date:3/27/2017)... ... ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from California ... she said. , She thinks the coming week is going to be a very joyful ... to help my students.” , The award will allow the 4th grade teacher at Tumwater ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... announce the launch of a months-long rebranding effort. This includes the introduction of ... focus group discussions and market research, we learned that a simple, proactive approach ...
(Date:3/27/2017)... ... , ... The homeowner improvement and repair market is expected to reach $317 ... for renovations is also on the rise. Per a 2017 report, 13% of all ... failed to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 Arena Pharmaceuticals, Inc. ... on developing novel, small molecule drugs across multiple therapeutic areas, ... Chief Executive Officer, will present a corporate update at the ... 3:40pm ET.  The conference will take place April 4-5, 2017 ... New York , NY.  A live ...
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... Bone Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone ... reach $724 million by 2022, growing at a CAGR of 3.6% during the ... ... Allied Market Research Logo ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
Breaking Medicine Technology: